Fate Therapeutics (FATE) Current Deferred Revenue (2012 - 2026)
Fate Therapeutics (FATE) posted Current Deferred Revenue of $582000.0 for Q1 2026, up 52.76% on a QoQ basis from $381000.0 in Q4 2025, and up 174.53% year-over-year from $212000.0 in Q1 2025.
Fate Therapeutics (FATE) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Fate Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $582000.0 for Q1 2026.
- Quarterly Current Deferred Revenue rose 174.53% year-over-year to $582000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582000.0 (up 174.53% YoY) and the FY2025 annual result came in at $381000.0, down 3.05% from the prior year.
- Current Deferred Revenue was $582000.0 for Q1 2026 at Fate Therapeutics, up from $381000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $42.2 million in Q4 2022 and bottomed at $5000.0 in Q3 2025.
- A 5-year average of $9.4 million and a median of $685000.0 in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue sank 99.17% — and 2026, when it jumped 174.53%.
- Fate Therapeutics' Current Deferred Revenue stood at $42.2 million in 2022, then plunged by 98.38% to $685000.0 in 2023, then tumbled by 42.63% to $393000.0 in 2024, then fell by 3.05% to $381000.0 in 2025, then surged by 52.76% to $582000.0 in 2026.
- Business Quant data shows FATE's Current Deferred Revenue at $582000.0 in Q1 2026, $381000.0 in Q4 2025, and $5000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 582,000.00 |
| Dec 31, 2025 | 381,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Mar 31, 2025 | 212,000.00 |
| Dec 31, 2024 | 393,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 159,000.00 |
| Dec 31, 2023 | 685,000.00 |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 42.23 Mn |
| Sep 30, 2022 | 35.24 Mn |
| Jun 30, 2022 | 33.66 Mn |
| Mar 31, 2022 | 22.58 Mn |
| Dec 31, 2021 | 21.48 Mn |
| Sep 30, 2021 | 23.55 Mn |
| Jun 30, 2021 | 23.03 Mn |
| Mar 31, 2021 | 21.03 Mn |
| Dec 31, 2020 | 21.14 Mn |